The primary endpoint analysis showed a dose-dependent increase in total sleep time from baseline on day one.

Incannex Healthcare announced positive results from a pharmacokinetics and safety study of IHL-42X, its oral fixed-dose combination of acetazolamide and dronabinol, aimed at treating obstructive sleep ...

Incannex Healthcare Inc. announced positive findings from its IHL-42X study for treating obstructive sleep apnea (OSA), paving the way for a future FDA 505(b)(2) new drug application. The company ...

Sleep apps offer data-driven insights for better rest, but may increase anxiety in some users. Study reveals varied effects ...

The American Academy of Sleep Medicine has indicated that an estimated 26 percent of adults between the ages of 30 and 70 years have sleep apnea. (Photo: Getty) You could say that it’s difficult to ...

Type D personality was linked to lower adherence and more side-effects in bilevel positive airway pressure therapy for sleep apnoea patients.

What impact can cannabis have for sleep apnea patients? This is what a recent report from the Office of Cannabis Management hopes to address as a team of researchers investigated the pros and cons of ...

Sleep apnea sufferers may soon have a new path to a good night’s sleep. A Massachusetts biotech startup is preparing to file for FDA approval of a once-nightly pill that could become the first ...